PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer

Eur Urol. 2020 Dec;78(6):845-846. doi: 10.1016/j.eururo.2020.08.034. Epub 2020 Sep 6.

Authors

David T Miyamoto¹, Richard J Lee²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: dmiyamoto@mgh.harvard.edu.
² Massachusetts General Hospital Cancer Center, Boston, MA, USA.

PMID: 32900554
DOI: 10.1016/j.eururo.2020.08.034

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Class I Phosphatidylinositol 3-Kinases
Humans
Male
Phosphoinositide-3 Kinase Inhibitors
Precision Medicine
Prostatic Neoplasms* / genetics
Prostatic Neoplasms* / therapy
Prostatic Neoplasms, Castration-Resistant*
Proto-Oncogene Proteins c-akt / genetics

Substances

Phosphoinositide-3 Kinase Inhibitors
Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human
AKT1 protein, human
Proto-Oncogene Proteins c-akt